We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Atomic Structures of Alternative Splicing Regulator Proteins May Lead to New Anticancer Drugs

By LabMedica International staff writers
Posted on 08 Feb 2016
Print article
Image: Top: Overview of the structure of T-STAR STAR domain in complex with AUUAAA RNA. Bottom left: close up view of the specific recognition of the RNA. Bottom right: close up view of the KH dimerization interface (Photo courtesy of the University of Leicester).
Image: Top: Overview of the structure of T-STAR STAR domain in complex with AUUAAA RNA. Bottom left: close up view of the specific recognition of the RNA. Bottom right: close up view of the KH dimerization interface (Photo courtesy of the University of Leicester).
A detailed structural analysis of two RNA-binding proteins that regulate alternate splicing of gene expression, which can lead to various types of cancer, is expected to aid in the development of drugs to suppress this activity.

Alternative splicing is a regulated process during gene expression that results in a single gene coding for multiple proteins. In this process, particular exons of a gene may be included within or excluded from the final, processed messenger RNA (mRNA) produced from that gene. Consequently the proteins translated from alternatively spliced mRNAs will contain differences in their amino acid sequence and, often, in their biological functions. Notably, alternative splicing allows the human genome to direct the synthesis of many more proteins than would be expected from its 20,000 protein-coding genes.

Investigators at the University of Leicester (United Kingdom) focused on the proteins Sam68 (the Src-Associated substrate in mitosis of 68 kDa) and T-STAR (testis-signal transduction and activation of RNA), which are members of the STAR family of proteins that directly link signal transduction with post-transcriptional gene regulation.

Sam68 is officially called KHDRBS1 (KH domain containing, RNA binding, signal transduction associated 1). It is a KH-type RNA binding protein that recognizes U(U/A)AA direct repeats with relative high affinity (nucleobases A = adenine, U = uracil). Sam68 is predominantly nuclear and its major function in the nucleus is to regulate alternative splicing by recognizing RNA sequences neighboring the included/excluded exon(s). The RNA binding activity of Sam68 is regulated by post-translational modifications such that Sam68 is often referred to as a STAR (Signal Transduction Activator of RNA) protein by which signals from growth factors or soluble tyrosine kinases, such as Src family kinases, act to regulate cellular RNA processes such as alternative splicing. T-STAR is a tissue-specific paralogue (one of a pair of genes that derives from the same ancestral gene and now resides at a different location within the same genome) that regulates the alternative splicing of neuronal pre-mRNAs.

The investigators reported in the January 13, 2016, online edition of the journal Nature Communications that they had determined at atomic resolution how T-STAR and Sam68 bound to RNA, revealing an unexpected mode of dimerization different from other members of the STAR family. They further demonstrated that this unique dimerization interface was crucial for their biological activity in splicing regulation, and suggested that the increased RNA affinity through dimer formation was a crucial parameter enabling these proteins to select their functional targets.

Senior author Dr. Cyril Dominguez, a lecturer in biochemistry at the University of Leicester, said, "The proteins that we have studied, called Sam68 and T-STAR, are very similar, and overexpression of Sam68 has been shown to correlate with poor prognosis in many types of cancers. Our results provide atomic resolution details on how Sam68 binds specifically to its RNA target. Furthermore, we show that Sam68 forms a homodimer that has never been described before and is crucial for its function in RNA splicing. This is important because this basic research set the grounds for structure-based drug design approaches. If we can identify or design drugs that bind specifically at the dimerization interface, we will be able to prevent the function of these proteins in cells, which could have implications for novel cancer treatments. Now that we have a high-resolution structure of Sam68 and T-STAR and a high-throughput binding assay, we are in discussion to collaborate with a major drug discovery consortium to screen a very large library of compounds to inhibit the function of Sam68."

Related Links:

University of Leicester


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Systemic Autoimmune Testing Assay
BioPlex 2200 ANA Screen with MDSS

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.